ES2171469T3 - Composicion administrada por via nasal y preparacion que la contiene. - Google Patents

Composicion administrada por via nasal y preparacion que la contiene.

Info

Publication number
ES2171469T3
ES2171469T3 ES94930340T ES94930340T ES2171469T3 ES 2171469 T3 ES2171469 T3 ES 2171469T3 ES 94930340 T ES94930340 T ES 94930340T ES 94930340 T ES94930340 T ES 94930340T ES 2171469 T3 ES2171469 T3 ES 2171469T3
Authority
ES
Spain
Prior art keywords
composition
pernasal
nasal
preparation
composition administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94930340T
Other languages
English (en)
Inventor
Katsuya Mukae
Mitsuhiro Mizumachi
Kohki Itoh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hisamitsu Pharmaceutical Co Inc
Original Assignee
Hisamitsu Pharmaceutical Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hisamitsu Pharmaceutical Co Inc filed Critical Hisamitsu Pharmaceutical Co Inc
Application granted granted Critical
Publication of ES2171469T3 publication Critical patent/ES2171469T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Abstract

UNA COMPOSICION PERNASAL QUE COMPRENDE UNA SUSTANCIA FARMACOLOGICAMENTE ACTIVA, AGUA Y UN ALCOHOL, E DONDE EL CONTENIDO DE ALCOHOL ES DE 10-70% VOL DE LA COMPOSICION TOTAL. ESTA COMPOSICION ES ALTAMENTE SEGURA Y PERMITE UNA RAPIDA ABSORCION DEL FARMACO Y RETENCION PROLONGADA DEL NIVEL DEL FARMACO EN SANGRE. POR LO TANTO, ESTA COMPOSICION Y UNA PREPARACION PERNASAL QUE CONTIENE LA MISMA PERMITE LA ADMINISTRACION PERNASAL DE FARMACOS QUE HAN SIDO DIFICILES DE ADMINISTRAR PERNASALMENTE Y SE ESPERAN MUESTREN UNA EFICACIA DEL FARMACO SATISFACTORIA.
ES94930340T 1993-10-21 1994-10-19 Composicion administrada por via nasal y preparacion que la contiene. Expired - Lifetime ES2171469T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP28778493 1993-10-21

Publications (1)

Publication Number Publication Date
ES2171469T3 true ES2171469T3 (es) 2002-09-16

Family

ID=17721701

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94930340T Expired - Lifetime ES2171469T3 (es) 1993-10-21 1994-10-19 Composicion administrada por via nasal y preparacion que la contiene.

Country Status (11)

Country Link
US (1) US5789375A (es)
EP (1) EP0724885B1 (es)
KR (1) KR100217258B1 (es)
CN (1) CN1098708C (es)
AT (1) ATE214289T1 (es)
AU (1) AU681452B2 (es)
CA (1) CA2174324A1 (es)
DE (1) DE69430132T2 (es)
DK (1) DK0724885T3 (es)
ES (1) ES2171469T3 (es)
WO (1) WO1995011042A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970032844A (ko) * 1995-12-29 1997-07-22 김준웅 지속성 경비투여제제
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
DE69928563T2 (de) * 1998-12-09 2006-07-27 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Abgeben von neurotropischen Wirkstoffen an das Zentralnervensystem
JP2003501404A (ja) 1999-06-04 2003-01-14 デルルックス ファーマシューティカル コーポレイション 薬剤の脱水粒子からなる製剤およびこれの調製方法
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
JP3498041B2 (ja) 2000-05-29 2004-02-16 科研製薬株式会社 プラルモレリン含有点鼻用製剤
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
EP1642593A1 (en) * 2003-06-06 2006-04-05 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
EP1687323A4 (en) 2003-08-08 2009-08-12 Life Technologies Corp METHODS AND COMPOSITIONS FOR DIRECT CLONING OF NUCLEIC ACID MOLECULES
EP2287341B1 (en) 2003-12-01 2013-02-13 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20060046969A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Antibacterial compositions for drug administration
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
EP1789075A4 (en) * 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US8124598B2 (en) 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
CA2756690C (en) 2008-03-28 2016-08-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
WO2012174158A2 (en) 2011-06-14 2012-12-20 Hale Biopharma Ventures, Llc Administration of benzodiazepine
WO2019157099A1 (en) 2018-02-06 2019-08-15 Aegis Therapeutics, Llc Intranasal epinephrine formulations and methods for the treatment of disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57188526A (en) * 1981-05-14 1982-11-19 Takeda Chem Ind Ltd Peptide-containing pharmaceutical preparation
JPS60224638A (ja) * 1984-04-23 1985-11-09 Kao Corp 経皮吸収促進剤およびこれを含有する外用剤
JPS61267528A (ja) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
JPH0643390B2 (ja) * 1986-04-08 1994-06-08 久光製薬株式会社 アザシクロアルカン誘導体
US4782047A (en) * 1986-05-22 1988-11-01 Syntex Pharmaceuticals International Ltd. Aqueous steroid formulations for nasal administration
CA1335076C (en) * 1987-04-01 1995-04-04 Hanna R. Kowarski Pharmaceutical composition and method for intranasal administration
US5112804A (en) * 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
JPH01160916A (ja) * 1987-12-18 1989-06-23 Tanabe Seiyaku Co Ltd ドーパミン経鼻投与製剤
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
EP0532546B1 (en) * 1990-05-10 1998-03-18 Bechgaard International Research And Development A/S A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols

Also Published As

Publication number Publication date
ATE214289T1 (de) 2002-03-15
KR100217258B1 (ko) 1999-09-01
EP0724885A1 (en) 1996-08-07
CN1098708C (zh) 2003-01-15
CN1133565A (zh) 1996-10-16
DE69430132D1 (de) 2002-04-18
AU681452B2 (en) 1997-08-28
EP0724885A4 (en) 1997-06-25
EP0724885B1 (en) 2002-03-13
DK0724885T3 (da) 2002-05-21
CA2174324A1 (en) 1995-04-27
AU7949294A (en) 1995-05-08
US5789375A (en) 1998-08-04
DE69430132T2 (de) 2002-08-29
KR960705585A (ko) 1996-11-08
WO1995011042A1 (fr) 1995-04-27

Similar Documents

Publication Publication Date Title
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
NO863620L (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
KR880002515A (ko) 흡수 및 작용이 빠른 설린다크 또는 나트륨 설린다크와 염기의 혼합물
DK567088A (da) Indretning til transdermal laegemiddelindgift
ES2117642T3 (es) Preparado farmaceutico que contiene n-glicofuroles y n-etilen glicoles.
NO890186L (no) Fremgangsmaate for fremstilling av en avgivelses- og/ellerdoseringsform for legemiddelaktive stoffer.
KR970025615A (ko) 암 전이 억제제
DE69322251T2 (de) Medizinische zusammensetzung
ES2119748T3 (es) Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua.
ES2139842T3 (es) Uso de la melatonina para tratar a pacientes que sufren drogodependencia.
KR970032872A (ko) 아세틸살리실산을 함유하는 피부 손상 처치용 약물
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
KR890006227A (ko) 페놀-함유 진해성 액체 조성물
KR890004705A (ko) 항바이러스성 제제
AR006202A1 (es) Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene
KR890007728A (ko) 진통제 제조방법
KR830008678A (ko) 진통 조성물
KR960003718A (ko) 말초신경병 및 중추신경변성병의 치료에 유용한 의약의 제조를 위한 이펜프로딜 및 그 부분입체이성질체의 이용
KR870005642A (ko) 디플루니살과 트로메타민의 혼합물
SE8304818L (sv) Medicin med magsarslekande, spasmolytisk och lokalanesteserande verkan
KR920700041A (ko) 치료화합물과 그의 조성 및 용도
BR9912260A (pt) Emplastro contendo um sistema terapêutico transdérmico e dose única para ministração
ATE226070T1 (de) Taxol enthaltende pharmazeutische injektionslösung

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 724885

Country of ref document: ES